RxDoctor Payments Data

Nehali Patel

Family · Germantown, MDNPI 1568969517

Payments from drug & device makers

$2,632in general payments, 2019–2025

Across 130 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$721
  • AbbVie$258
  • Pfizer$233
  • Exact Sciences$214
  • Lilly USA, LLC$168
  • Daiichi Sankyo Inc.$150
  • plus $889 from 15 others

What the payments were for

  • Food & beverage$2,57298%
  • Education$602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,632 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$32,267
Medicare patients
125
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$26,762
JardianceEmpagliflozin19$26,477
Atorvastatin Calcium153$1,344
SynthroidLevothyroxine Sodium12$863
Losartan Potassium71$857
Rosuvastatin Calcium48$809
Levothyroxine Sodium51$746
Albuterol Sulfate HfaAlbuterol Sulfate32$619
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide28$609
Amlodipine Besylate93$547
Metoprolol Succinate47$536
Metformin Hcl59$340
Metformin Hcl ErMetformin Hcl35$320
Lisinopril48$317
Atenolol26$298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$721$26,76212 claims
Boehringer IngelheimJardiance$21$26,47719 claims
AbbVieSynthroid$258$86312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.

Other family in Germantown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →